Pasar al contenido principal

Alexandre Martínez Marti

Dr Martinez is attending physician of the Iung cancer tumor group of Vall d’Hebron University Hospital (HUVH) and also co-investigator of a large number of phase I, phase II and phase III clinical trials and principal investigator of several of them.

Instituciones de las que forman parte

Vall Hebron Institut de Recerca
Investigador
Vall Hebron Institut d'Oncologia
Alexandre Martínez Marti

Alexandre Martínez Marti

Alexandre Martínez Marti

Instituciones de las que forman parte

Vall Hebron Institut de Recerca
Investigador
Vall Hebron Institut d'Oncologia

Dr Martinez is attending physician of the Iung cancer tumor group of Vall d’Hebron University Hospital (HUVH) and also co-investigator of a large number of phase I, phase II and phase III clinical trials and principal investigator of several of them.

I graduated from de degree of Medicine at the Autonomous University of Barcelona (UAB) in 2006 and in 2011 I completed my residency in Medical Oncology at the Catalan Institute of Oncology - Germans Trias I Pujol University Hospital directed by Dr. Rafael Rosell. Influenced by his teachings on lung cancer in June 2011, I joined the Department of Medical Oncology at Vall d'Hebron University Hospital - Vall d’Hebron Institute of Oncology (VHIO) as a medical oncologist where I have been able to learn since then from a leader in the field of lung cancer such as Dr. Enriqueta Felip.
In the Thoracic Tumor Unit in Vall d’Hebron led by Dr. E. Felip, I am involved as co-investigator of a large number of phase I, phase II and phase III clinical trials and principal investigator of several of them. Currently focused my activity in the treatment of early stage and locally-advanced NSCLC as well as participating in clinical trials with new therapies in this setting.
Since 2019 I have also worked as a tutor for residents of the Medical Oncology Unit.

Proyectos

Ensayo clínico para comparar la inmunogenicidad de una vacuna anti-hepatitis B adyuvada con la de carga antigénica aunmentada en pacientres inmunodeprimidos.

IP: -
Colaboradores: Manuel Hernández González, Rosa Lopez Martinez , Lluis Armadans Gil, Alexandre Martínez Marti, Laia Pinos Tella, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Blanca Borras Bermejo, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 73205
Referencia: PI18/01887
Duración: 01/01/2019 - 30/06/2023

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.